Quinuclidine derivatives as muscarinic M3 receptor antagonists
申请人:Astrazeneca AB
公开号:US08329729B2
公开(公告)日:2012-12-11
The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.
[EN] QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE QUINUCLIDINE UTILISÉS COMME ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES M3
申请人:ASTRAZENECA AB
公开号:WO2009138707A9
公开(公告)日:2010-01-28
US8329729B2
申请人:——
公开号:US8329729B2
公开(公告)日:2012-12-11
QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
申请人:Bull Richard James
公开号:US20110172237A1
公开(公告)日:2011-07-14
The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for’ the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.